跳至主要内容
临床试验/ISRCTN30191436
ISRCTN30191436已完成4 期

Aggression Following TBI: Effectiveness of Risperidone

Central and North West London NHS Foundation Trust0 个研究点目标入组 14 人开始时间: 2016年12月19日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
14

研究概览

简要总结

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Aged between 18 and 65 years
  • 2. A confirmed clinical diagnosis of TBI which occurred at least six months prior to recruitment, evidenced as a rating of moderate/severe or mild (probable) based on Mayo Clinic criteria
  • 3. Referred to the clinician for the management of aggression and for whom the clinician is considering a pharmacological intervention for this problem after investigating and addressing physical, psychological and social triggers
  • 4. Competent and willing to provide written, informed consent
  • 5. The patient or their carer is able to understand how to manage prescribed medication

排除标准

  • 1. Suffering from Post-Traumatic Amnesia (PTA), which constitutes a sub-acute confusional state
  • 2. Co-morbid severe mental illness such as schizophrenia and other psychoses, bipolar disorder, major depressive disorder, personality disorder, and dementia, and where the clinicians are treating primarily a psychiatric disorder rather than aggressive behaviour
  • 3. Already prescribed an antipsychotic drug or any other drug that may interact with risperidone at the time of randomisation. A wash-out period of at least two weeks is required prior to randomisation.
  • 4. Any other contraindication for using risperidone including a previous history of severe adverse events
  • 5. Has no fixed abode or any other reason for which compliance with trial medication and monitoring could pose a major problem
  • 6. Is pregnant or trying to conceive, breastfeeding, or a woman of childbearing potential not using a highly effective birth control
  • 7. Lactose intolerance
  • 8. Known cardiovascular disease (e.g., heart failure, myocardial infarction, conduction abnormalities including family history of QT prolongation, dehydration, hypovolaemia, bradycardia, or electrolyte disturbances (hypokalaemia, hypomagnesaemia), or cerebrovascular disease
  • 9. A clinically significant low white blood cell count or a drug-induced leukopenia/neutropenia
  • 10. A history of seizures

研究者

相似试验